|Articles|January 7, 2021

Quiz: Is It COVID-19 or the Flu?

A seven-question quiz comparing the respiratory viruses. Can you pass it?

In many ways, the coronavirus 2019 (COVID-19) pandemic and influenza have been linked to one another since the first outbreaks last year; their both being contagious respiratory infections with overlapping primary symptoms has led to sometimes false interpretations of actual characteristics and risks associated with COVID-19.

During this flu season—a period which experts stressed beforehand would be vital to reduce overlapping virus spreads, and the public responded to with lessened concern—understanding the true disparities between the respiratory viruses is vital, as the pandemic continues to overwhelm the US healthcare system.

Below is a seven-question quiz, courtesy of sister publication Medical Economics, on the unique disparities and similarities of COVID-19 and flu.

Interested in more clinical insights? Want to learn more about COVID-19, flu, and more topical disease? Sign up for the HCPLive tailored daily newsletter.

________________________________________________

Question 1: A patient presents with a cough, sore throat, fatigue, and loss of taste. These symptoms are mostly likely caused by:

A. COVID-19
B. Influenza

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.

Related to this article

September 21st, 2026

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.

September 26th, 2026

Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry

Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

September 26th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

September 25th, 2026

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

Image Credit: US Food and Drug Administration

September 25th, 2026

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

September 25th, 2026

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

September 25th, 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.